FDA Declares End to Tirzepatide Shortage

Karmactive Staff

Photo Source: Felton Davis, CC BY 2.0

"The FDA stated Thursday that Eli Lilly's tirzepatide-based drugs, Zepbound and Mounjaro, are out of shortage."

"This ruling means that compound pharmacies will have to stop production of alternative versions within 60 to 90 days."

Photo Source: High Contrast, CC BY 3.0 DE)

Photo Source: Leeloo The First (Pexels)

"This decision has gone through a long regulatory procedure."

"The alternative versions were allowed to be produced by compounding pharmacies during the time of re-evaluation."

Photo Source: Anna Shvets (Pexels)

Photo Source: Momoneymoproblemz, CC BY-SA 4.0

"Shares of Eli Lilly traded at $758.90 and were down 1% while Novo Nordisk declined 3.5%."

"The FDA spokesperson said compounding pharmacies have until February 18, 2024, to use up their remaining stock."

Photo Source: Felton Davis, CC BY 2.0

Photo Source: Nick Youngson, CC BY-SA 3.0 Alpha Stock Images

"Most insurers pay for Lilly's and Novo's diabetes drugs, but many don't pay for weight-loss drugs."

"Eli Lilly stood firm throughout the litigation."

Photo Source: Sora Shimazaki

Photo Source: Wendy Maxwell, Pexels

"The FDA ruling is a watershed moment in the broader debate over access to medications, patient access, and pharmaceutical regulation in the United States."

Next Story

Supreme Court Weighs FDA's Controversial Flavored Vape Ban Amid Youth Risks